The
global ventilator-associated pneumonia market is expected to exhibit significant
growth over the forecast period. The market was valued at approximately USD
968.92 million in 2018 and is projected to register a 9.45% CAGR over the
forecast period.
Ventilator-associated
pneumonia is a type of lung infection that affects patients who are on
ventilators. It is caused because of lung diseases, neurological diseases, and
trauma.
Factors such as the growing prevalence of ventilator-associated pneumonia and
increasing incidences of traumatic brain injury are expected to drive the
market growth. According to a report published by the National Center for
Biotechnology Information (NCBI) in November 2017, the incidence rate for ventilator-associated
pneumonia ranges from 5% to 67%, depending upon the case. Moreover, the
increasing research and development expenditure for the development of
effective treatment for the disease is further boosting the market growth.
Browse
Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1377
However,
factors such as expensive diagnostic tests, high ventilator charges, and
inappropriate reimbursement scenarios are expected to hamper the market
growth.
Segmentation
The global ventilator-associated pneumonia market has been segmented into
diagnosis, end users, and region.
Based on diagnosis, the global ventilator-associated pneumonia market has been
segmented into clinical, radiological, microbiological, and others. The
microbiological diagnosis segment is further classified into blood &
pleural fluid cultures, nonquantitative or semi-quantitative airway sampling,
and quantitative cultures of airway specimens.
The global ventilator-associated pneumonia market, by end user, has been
categorized into hospitals & clinics, research & academic
institutes, ambulatory care centers, and others.
The market has been segmented, by region, into the Americas, Europe,
Asia-Pacific, and the Middle East & Africa. The ventilator-associated
pneumonia market in the Americas has further been segmented into North America
and Latin America, with the North American market divided into the US and
Canada.
The European ventilator-associated pneumonia market has been segmented into
Western Europe and Eastern Europe. The market in Western Europe has further
been classified into France, Germany, Spain, the UK, Italy, and the rest of
Western Europe.
The ventilator-associated pneumonia market in Asia-Pacific has been segmented
into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The ventilator-associated pneumonia market in Middle East & Africa is
segmented into the Middle East and Africa.
Key Players
Adenium Biotech ApS (Denmark), Merck & Co., Inc. (US), AstraZeneca
(UK), MedImmune (US), Nabriva Therapeutics AG (Ireland), Thermo Fisher
Scientific (US), Bayer AG (Germany), Wockhardt (India), Shionogi Inc. (Japan),
Cardeas Pharma (US) are some of the key players operating in the global
ventilator-associated pneumonia market.
Regional
Market Summary
Geographically,
the market has been segmented into the Americas, Europe, Asia-Pacific, and the
Middle East & Africa. The Americas is anticipated to dominate the global
ventilator-associated pneumonia market owing to the prevalence of
ventilator-associated pneumonia and growing initiatives by the government and
non-government organizations to control the growth of the disease.
Europe is expected to hold the second-largest share of the
ventilator-associated pneumonia market. The presence of a large patient
population suffering from lung diseases and well-developed healthcare industry
drives the market growth in this region.
Asia-Pacific is expected to be the fastest-growing regional market owing to the
growing initiatives taken by the government and non-government organizations to
create awareness regarding the prevalence rate of various infectious diseases
and increasing incidences of ventilator-associated pneumonia. According to a
report published by the Indian Chest Society in August 2016, the incidence rate
of ventilator-associated pneumonia is approximately 13.6 per 1000 mechanical
ventilation days in India.
The ventilator-associated pneumonia market in the Middle East & Africa
holds the least share of the market. The Middle Eastern market is expected to
hold a significant market share of this region owing to growing government initiatives
for developing the healthcare industry in this region. The African market is
expected to grow due to high prevalence of infectious diseases.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com